Adam Renslo

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo The COVID-19 pandemic emphasized the need for effective antivirals acting at new targets. We recently described AVI-4206, a 9H-pyrimido[4,5-b]indole-based inhibitor of the SARS-CoV-2 macrodomain Mac1,...

In our latest work on viral macrodomains, we descibe the orally bioavailable and efficacious lead AVI-6451, evolved from the initial lead AVI-4206. Excited to be collaborating with @inductivebio.bsky.social to further advance this lead toward candidacy. Stay tuned!

pubs.acs.org/doi/10.1021/...

The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in ...

The version of record is now out in eLife! For the next chapter in this story check out www.biorxiv.org/content/10.1...

In @elife.bsky.social: The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2 doi.org/10.7554/eLif...

Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance Antimalarial endoperoxides with activity against artemisinin-resistant clinical isolates are characterized in vitro and in vivo.

Check out our latest work on endoperoxide antimalarials - Congrats to Matt, Poulami, and many other lab members and collaborators!

Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance | Science Advances www.science.org/doi/10.1126/...

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy This study describes a class of potent, bioavailable SARS-CoV-2 MPro inhibitors having an unusual mechanism of inhibition.

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy | Science Advances www.science.org/doi/10.1126/...